Wednesday, June 10, 2026

Patent intelligence · US

US 2020024256

TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

granted A61K/314545A61P/2500A61P/2518
Status granted
Pipeline programs 6
Years to expiry 14
Applicant portfolio 9
Patent details — US 2020024256
Jurisdiction
US
Status
granted
Grant date
Jan 23, 2020
Expiration
Jan 18, 2040
CPC classes
A61K/314545, A61P/2500, A61P/2518
View on Google Patents ↗

Quick answer

US 2020024256 (TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 23, 2020. Expires Jan 18, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K/314545, A61P/2500, A61P/2518

More from BIOPROJET PHARMA [FR]

Related pharmaceutical patents in our USPTO index.

  1. EP 4732903

    COKRISTALLE VON PITOLISTANTHYDROCHLORID

    BIOPROJET PHARMA [FR] · Expires Apr 24, 2046

    granted
  2. EP 4681704

    NEUE FORMULIERUNGEN VON PITOLISANT

    BIOPROJET PHARMA [FR] · Expires Jan 16, 2046

    granted
  3. US 2025120959

    NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

    BIOPROJET PHARMA [FR] · Expires Apr 12, 2045

    granted
  4. US 2024327366

    POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE

    BIOPROJET PHARMA [FR] · Expires Sep 28, 2044

    granted
  5. EP 3906927

    VERWENDUNG VON DOPAMIN-D3-TEILAGONISTEN ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS

    BIOPROJET PHARMA [FR] · Expires Nov 5, 2041

    granted
  6. EP 3378477

    NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN

    BIOPROJET PHARMA [FR] · Expires Sep 21, 2038

    granted
  7. EP 2511275

    Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten

    BIOPROJET SOC CIV [FR] · Expires Oct 12, 2032

    granted

Frequently asked questions

What is US patent 2020024256?

US 2020024256 (TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 23, 2020. Expires Jan 18, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2020024256?

BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.

When does US 2020024256 expire?

Our index shows an expiration date of Jan 18, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.